Other investigators have provided convincing evidence that the effects of targeted inhibitors on melanoma cell lines is different in 2-dimension and 3-dimension models [27], with higher resistance to BRAF inhibitors in 3 dimension models mediated by the PI3K/AKT pathway [28]. The gene discussed is AKT1; the disease is melanoma.